NBIX News and Press, Neurocrine Biosciences Inc. From 04/25/24

2024-04-25 18:28:44 ET Summary Neurocrine Biosciences, Inc. achieved positive results achieved from phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with Major Depressive Disorder. NBI-1065845 may offer some advantages over currently approved MDD therapies, su...

2024-04-24 19:08:44 ET More on Neurocrine Biosciences Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript Neurocrine Biosciences upgraded at Wells Fargo on pipeline Neuro...

2024-04-24 15:15:12 ET Wells Fargo analyst issues OVERWEIGHT recommendation for NBIX on April 23, 2024 04:12PM ET. The previous analyst recommendation was Buy. NBIX was trading at $139.345 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...

2024-04-24 11:59:30 ET More on Neurocrine Biosciences Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript Neurocrine succeeds in mid-stage trial for Takeda-partnered depression d...

Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community PR Newswire WHAT THE C@H?! provides a platform for the congenital adrenal hyperplasia (CAH) community to find educational information, share...

2024-04-23 14:22:14 ET More on Neurocrine Biosciences Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript Sentia Medical Sciences and Neurocrine Biosciences extend research colla...

2024-04-23 08:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder PR Newswire SAVITRI ™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale ( MA...

2024-04-16 16:09:56 ET More on Neurocrine Biosciences Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript Neurocrine Biosciences Q4 2023 Earnings Preview Seeking Alpha&#x...

2024-04-15 06:38:19 ET More on smallcaps and midcaps IWM A Bargain As The S&P 500's P/E Hits 21x It's Selling Season For The Russell 2000 And ETFs That Track It IWM: Are Small Caps Being Overlooked In The Megacap Market Frenzy? Overbought conditions flash...